AVTX Stock Summary and Trading Ideas (Avalo Therapeutics | NASDAQ:AVTX)

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Avalo Therapeutics trades on the NASDAQ stock market under the symbol AVTX.

As of February 27, 2026, AVTX stock price declined to $17.50 with 1,004,296 million shares trading.

AVTX has a beta of 1.45, meaning it tends to be more sensitive to market movements. AVTX has a correlation of 0.09 to the broad based SPY ETF.

AVTX has a market cap of $323.97 million. This is considered a Small Cap stock.

In the last 3 years, AVTX traded as high as $1,130.31 and as low as $3.39.

The top ETF exchange traded funds that AVTX belongs to (by Net Assets): VTI, VXF, IWC, DFAS, MEDI.

AVTX has outperformed the market in the last year with a price return of +165.2% while the SPY ETF gained +18.5%. However, in the short term, AVTX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -5.7% vs +1.2% return in SPY. But in the last 2 weeks, AVTX shares have fared better than the market returning +22.7% compared to SPY +0.6%.

AVTX support price is $16.50 and resistance is $18.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVTX shares will trade within this expected range on the day.